Your shopping cart is currently empty

GSK4028 is the enantiomeric negative control of GSK4027, a PCAF/GCN5 bromodomain chemical probe, with a pIC50 of 4.9 in a TR-FRET assay.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 5 mg | $1,470 | 8-10 weeks | 8-10 weeks | |
| 10 mg | $2,200 | 8-10 weeks | 8-10 weeks | |
| 25 mg | $3,740 | 8-10 weeks | 8-10 weeks |
| Description | GSK4028 is the enantiomeric negative control of GSK4027, a PCAF/GCN5 bromodomain chemical probe, with a pIC50 of 4.9 in a TR-FRET assay. |
| Targets&IC50 | PCAF/GCN5:4.9(pIC50) |
| In vitro | GSK4028 also demonstrates potency toward BRD4 BD1 and BRD9 inTR-FRET assay with pIC50s of <4.3 and 4.5±0.13, respectively.GSK4028 is the enantiomeric negative control of GSK4027, which is a PCAF/GCN5 bromodomain chemical probe, the pIC50 of GSK4028 is 4.9. |
| Molecular Weight | 377.28 |
| Formula | C17H21BrN4O |
| Cas No. | 2079886-19-2 |
| Smiles | CN1C[C@H](C[C@H](C1)c1ccccc1)Nc1cnn(C)c(=O)c1Br |
| Relative Density. | 1.45 g/cm3 (Predicted) |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.